Contraindication of Traditional Testosterone Replacement Therapy in Men Seeking Fertility

Mechanism of Fertility Impairment

Exogenous testosterone suppresses the hypothalamic‑pituitary‑gonadal axis, inhibiting LH and FSH secretion and leading to reduced intratesticular testosterone, which is essential for normal spermatogenesis; this often results in oligospermia or azoospermia. 1, 2, 3

Most men who become azoospermic on testosterone therapy recover spermatogenesis after stopping the drug, but the time to recovery is highly variable and can range from several months to years. 1, 2

For secondary hypogonadism, hCG is the recommended first‑line therapy to restore endogenous testosterone production and maintain spermatogenesis. 4, 5, 6
Initial hCG dosing is 500–2,500 IU administered 2–3 times per week. 1, 2
The magnitude of testosterone and sperm response to hCG correlates with baseline testicular size. 1, 2
After testosterone levels normalize on hCG, adding FSH injections when indicated optimizes fertility outcomes. 1, 4, 5
Combined hCG + FSH therapy yields the best results for preserving fertility in hypogonadal men. 4, 5, 6
hCG is the only agent among these alternatives that currently holds FDA approval for use in men. 3, 7

SERMs such as clomiphene citrate can stimulate endogenous testosterone production while preserving spermatogenesis. 8, 3, 7
These agents increase intrinsic testosterone without suppressing sperm production. 3

Aromatase inhibitors provide another option to boost endogenous testosterone while maintaining the potential for fertility. 8, 3, 7
AIs may be used alone or in combination with other fertility‑preserving agents. 3

Diagnosis of hypogonadism requires two separate fasting morning total testosterone measurements that are consistently below the normal reference range. 4, 5
Determination of hypogonadism type involves measuring serum LH and FSH and evaluating for pituitary pathology, allowing distinction between primary (testicular) and secondary (hypothalamic‑pituitary) causes. 4, 1, 2
In men with secondary hypogonadism who desire fertility:
For men uncertain about future fertility plans, sperm banking should be considered before any hormonal intervention if baseline semen analysis does not show azoospermia. 9
In such cases, prefer hCG, SERMs, or AIs over traditional testosterone therapy. 8, 3, 7
For men who anticipate fertility needs only in the distant future, testosterone therapy may be offered only after explicit counseling about its inhibitory effect on spermatogenesis and the unpredictable, potentially prolonged recovery period after discontinuation. 1, 2

Traditional testosterone replacement therapy is an absolute contraindication for men actively trying to conceive. 1, 4, 8, 5
Patients should be informed that recovery of sperm production after stopping testosterone can take months to years and is not reliably predictable. 1, 2
Fertility‑preserving alternatives (hCG, SERMs, aromatase inhibitors) can maintain or restore endogenous testosterone while protecting spermatogenesis. 4, 8, 5, 3

Assuming that spermatogenesis recovers quickly after testosterone cessation is incorrect; recovery may require many months or longer. 1, 2
Failing to inquire about a patient’s fertility intentions before initiating testosterone therapy can lead to unintended infertility. 4, 5
Not all hypogonadal men are infertile; a baseline semen analysis is essential to assess fertility status before treatment. 9
Compounded testosterone preparations should be avoided when FDA‑approved alternatives (e.g., hCG) are available, due to variability in potency and quality. 3, 7

Clomiphene citrate should not be used in men who have primary (testicular) hypogonadism—characterized by elevated gonadotropins—because the testes are unable to respond to the LH and FSH increases induced by the drug, resulting in lack of therapeutic benefit. 10 (Evidence strength: not specified)